Diagnosis and Management of Pituitary Disorders - part 5 docx

... controls for all-cause and infection-related mortality(age-adjusted RR 1.9, 95% CI 1 .5 2.3 and RR 2.4, 95% CI 1.2–4.7 for women respectively and RR 1.7, 95% CI1.4–2.1 and RR 1.7, 95% CI 0.8–4.7 for ... gangrene: report of 45 cases. Dis Colon Rectum2003;46 (5) :649 52 . 155 . Yeniyol CO, Suelozgen T, Arslan M, Ayder AR. Fournier’s gangrene: experience with 25 patients and use of Fournier’s gangreneseverity ... Diabetes 20 05; 54 : 359 2–3601.4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications...

Diagnosis and Management of Pituitary Disorders - part 2 docx

... Metabolism 2001 ;50 : 856 –861.130. Pories WJ, MacDonald KG, Jr., Morgan EJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J ClinNutr 1992 ;55 :58 2S -5 8 5S.131. Shimomura ... Sweetland MA, McDaniel ML. Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosylcomplexes in islets of Langerhans. Role of nitric oxide in interleukin-1 beta-induced inhibition of ... 2004;101: 657 0– 657 5.71. Koves TR, Li P, An J, et al. Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and...

Diagnosis and Management of Pituitary Disorders - part 3 docx

... was 2 .53 , 2.46, and 5. 04 in men with HbA1c concentration of 5. 0 5. 4%, 5. 5–6.9%, and ≥7% respectively (55 ). In a Finnishstudy (56 ) with a 3 .5 yr follow up, 3.4% of 1,069 nondiabetic subjects and ... 20 05; 81(3) :59 0 59 6.40. Wannamethee SG, Shaper AG. Type of alcoholic drink and risk of major coronary heart disease events and all-cause mortality. AmJ Public Health 1999;89:6 85 690.41. Anderson ... Diabetes Care 2002; 25: 148–198.61. Foster-Powell H, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr2002;76 :5 56 .62. Brand-Miller J, Hayne...

Diagnosis and Management of Pituitary Disorders - part 7 docx

... Captopril RRR 46% [5, 69]183 ( 25. 3) Mortality 9.4% LosartanELITE-2 CHF 3 152 1 .5 Yr 15. 9% Captopril HR 1.13 [0. 95, 1. 35] 749 (23.8) Mortality 17.7% Losartan p = 0.016Val-HeFT CHF 50 10 2 Yr 19.4% ... Rev Biochem 1982 ;51 :55 5 58 5.19. Yabe D, Brown MS, Goldstein JL. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterolregulatory element-binding proteins. ... Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Lancet 1999; 352 :1419–14 25. 191. Rodriguez A, Boullon F, Perez-Balino...

Diagnosis and Management of Pituitary Disorders - part 1 potx

... 120 mg/dL, and fasting insulin fallingby 50 %, when a group of Aborigines with diabetes returned to a hunter-gatherer lifestyle for 7 wk (39).0 5 10 15 20 25 30 75+ 65 7 455 –64 45 54 35 44 25 34Age ... Science UniversityBeaverton, ORISBN: 97 8-1 -5 8 82 9-7 9 4 -5 e-ISBN: 97 8-1 -6 032 7-0 4 3-4 Library of Congress Control Number: 200892 350 1©2008 Humana Press, a part of Springer Science+Business Media, LLCAll ... for the ß-cell loss through a combination of partial ß-cell regeneration and hyperfunction of theremaining ß-cells, and thus remain normoglycemic under normal circumstances. The partial ß-cell...

Diagnosis and Management of Pituitary Disorders - part 4 potx

... inHbA1cPregnancyCategorymetformin 50 0, 850 , 1000 Y 0.48 1.0 – 2.0 Bmetformin SR 50 0, 750 Y 0.98 1.0 – 2.0 Bpioglitazone 15, 30, 45 N 5. 95 1 .5 Crosiglitazone 2, 4, 8 N 5. 99 1 .5 Cglyburide 1. 25, 2 .5, 5 Y 0.2 1.0 ... available in strengths of 50 0 mg, 850 mg, and 1,000 mg tablets, as extended release form instrengths of 50 0 mg, 750 mg, and 1,000 mg, and a liquid form with 50 0 mg of metformin per 5 mL. Therecommended ... oxide levels (55 ,56 ), 4) decrease inflammatory markers such TNF, C-reactive protein, soluble CD40 ligand, and plasmamonocyte chemoattractant protein-1 (MCP-1) (46,47 ,57 ,58 ), and 5) enhance fibrinolysis...

Diagnosis and Management of Pituitary Disorders - part 6 pps

... Care 2004;27: 153 5– 154 0. 55 . Boyd CM, Leff B. Quality of care for older patients with diabetes mellitus with comorbidity. J Am Geriatr Soc 2006 ;54 :55 3 55 4;author reply 55 4. 56 . Peyrot M, Rubin ... 258 Goff and Cushmanover either monotherapy (79), a trial of the combination of trandolapril and verapamil showed no benefit of addingverapamil to trandolapril or even of verapamil ... events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362: 152 7– 153 5.61. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens...

Diagnosis and Management of Pituitary Disorders - part 8 ppt

... (%)–20ControlBandingVertical bandedgastroplastyGastricbypass– 25 –30– 35 –40– 45 0.0No .of SubjectsControlBandingVertical banded gastroplasty627 156 451 34 58 5 150 43834 59 4 154 43834 58 7 153 43834 57 714942933 56 3 150 41732 54 214741232 53 514440129627 156 451 34Gastric ... and Intermittent Treatment -3 0 -2 5 -2 0 -1 5 -1 0 -5 004wk8wk12wk16wk20wk24wk28wk 32wk36wklb.PlaceboQ O Mo. ContinuedMunro JF et al. Br Med J 1968 Feb 10;1 (55 88): 352 -4 Fig. 3. Intermittent ... Surg 20 05; 15: 502 50 5.11. Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.Obes Surg 20 05; 15: 310–3 15. 12. Wanless...

Diagnosis and Management of Pituitary Disorders - part 9 potx

... rare disorders has enhanced our understanding of the regulation of insulin secretion and glucose homeostasis, and may provide clues to a better understanding of the genetic basis of type 1 and ... women with the polycysticovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol 1999 ;50 :51 7 52 7.101. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz ... (c-GMP)-specific phosphodiesterase type 5 (PDE -5 ) revolutionizedthe management of ED such that the majority of diabetic men with ED can now be treated effectively with oralmedication (3 5) .In...

Diagnosis and Management of Pituitary Disorders - part 10 potx

... accumulation, 58 Nonalcoholic fatty liver disease (NAFLD), 351 diagnosis of, 355 – 358 natural history of, 358 – 359 related cirrhosis, 353 therapies for, 359 Nonalcoholic steatohepatitis (NASH), 158 , 351 Nonsulfonylurea ... practice setting, the office setting is ideal for on-going education and self-directed goal-setting for behavior change (4 ,54 ,55 ,59 ).The purpose of on-going diabetes self -management support (DSMS) ... self -management education (DSME), 456 – 459 Diabetes self -management support (DSMS), 461–462Diacylglycerol acyltransferase (DGAT), 53 54 Diagnostic and Statistical Manual of Mental Disorders (DSM-IV),...

Xem thêm